Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System-Reference-Cited by-同舟云学术

Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System

Published:2011 Issue:5 Volume:6 Page:381-389
ISSN:1661-3805
Container-title:Breast Care
language:en
Short-container-title:Breast Care

Author:

Lux Michael P.,Reichelt Claudia,Karnon Jon,Tänzer Thorsten D.,Radosavac Dragan,Fasching Peter A.,Beckmann Matthias W.,Thiel Falk C.

Publisher

S. Karger AG

Subject

Oncology,Surgery

Reference29 articles.

1. Is the biology of breast cancer changing? A study of hormone receptor status 1984–1986 and 1996–1997

2. Tamoxifen for early breast cancer: an overview of the randomised trials

3. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

4. BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation;BMC Health Services Research;2023-06-26

2. Krankheitslast von Brustkrebs in Deutschland: Epidemiologie und Kosten;Forum;2023-06-20

3. Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach;Frontiers in Public Health;2023-01-06

4. The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women;Value in Health Regional Issues;2021-09

5. Retrospective cost-analysis of the EndoPredict test in patients with primary breast cancer in a German breast center;Journal of Public Health;2020-02-08